News stories about Forward Pharma A/S (NASDAQ:FWP) have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Forward Pharma A/S earned a coverage optimism score of -0.05 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.2165662652713 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Forward Pharma A/S (FWP) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP28 (nasdaq.com)
- Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018 (markets.financialcontent.com)
- Forward Pharma A/S (FWP) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Forward Pharma A/S (FWP) Downgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 3rd. ValuEngine upgraded shares of Forward Pharma A/S from a “hold” rating to a “buy” rating in a research report on Friday. Jefferies Group reaffirmed a “hold” rating and set a $6.00 price target (up from $5.00) on shares of Forward Pharma A/S in a research note on Wednesday, September 27th. Finally, Zacks Investment Research cut shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, November 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $17.00.
WARNING: This piece was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://weekherald.com/2017/12/04/forward-pharma-as-fwp-earning-somewhat-negative-news-coverage-report-shows.html.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.